読み込み中
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
終値時点
$24.76
−$4.93 · -16.60%
時間外
$24.14
−$0.62 · -2.50%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
日中レンジ
現在 $24.76
52週レンジ
現在 $24.76
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
39
割高
センチメント
72
強気
リスク
56
やや高いリスク
モメンタム
49
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
日中レンジ
現在 $24.76
52週レンジ
現在 $24.76
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 347.7万 USD | 1065.5万 USD | — | 1250万 USD | — |
| 売上原価 | 53.7万 USD | — | 2723万 USD | 326.9万 USD | 329.7万 USD |
| 粗利益 | 294万 USD | 1065.5万 USD | −2723万 USD | 923.1万 USD | −329.7万 USD |
| 研究開発 | 2936.5万 USD | 2113.2万 USD | 2723万 USD | 3701.3万 USD | 3688万 USD |
| 販売・一般管理 | 1620.4万 USD | 1506.2万 USD | 1579.8万 USD | 1982.6万 USD | 1421.4万 USD |
| 営業費用 | 4503.2万 USD | 3619.4万 USD | 1855万 USD | 5357万 USD | 5109.4万 USD |
| 受取利息 | 302万 USD | 169.3万 USD | 234万 USD | 78.1万 USD | 7.2万 USD |
| 減価償却費と償却費 | 53.7万 USD | 144.2万 USD | 191.1万 USD | 195.5万 USD | 206.6万 USD |
| 営業利益 | −4209.2万 USD | −2553.9万 USD | −4578万 USD | −4433.9万 USD | −5439.1万 USD |
| 純利益 | −2.42億 USD | −6356.4万 USD | −4304.2万 USD | −3600.4万 USD | −5251万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI621.77万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM571.19万0.01%787.4億 USD0.19%$277.9-0.37%
Janus Henderson Small/Mid Cap Growth Alpha ETFJSMD495.89万0.47%10.5億 USD0.30%$90.19-1.37%
Vanguard Extended Market ETFVXF226.67万0.00%954億 USD0.05%$233.52-0.63%
iShares Russell 2000 Growth ETFIWO203.96万0.01%139.17億 USD0.24%$353.71-0.86%
Vanguard Russell 2000 ETFVTWO93.31万0.01%180億 USD0.06%$112.27-0.35%
iShares Micro-Cap ETFIWC70.29万0.05%13.17億 USD0.60%$181.66-0.73%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC38.58万0.04%10.49億 USD0.20%$86.26-0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMJanus Henderson Small/Mid Cap Growth Alpha ETFJSMDVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
